The dose dependence of the hepatopromoting effects of phenobarbital (PB) was investigated in a rat liver mediumterm bioassay (Ito test) to elucidate a practical threshold level. F344 rats were given a single i.p. injection of diethylnitrosamine (200 mg/kg body wt) and subjected to twothirds partial hepatectomy at week 3. 
Introduction
Carcinogens can be grouped into two classes, genotoxic and non-genotoxic agents (1) . It is generally considered that *Abbreviations: DEN, diethylnitrosamine; GST-P, glutathione S-transferase placental form; PB, phenobarbital; TGF, transforming growth factor. carcinogenesis is a multistep process, separated into three stages: initiation, promotion and progression (1) (2) (3) . Many nongenotoxic agents appear to function at the tumor promoting stage (4) . Phenobarbital (PB*) is a sedative and anticonvulsant, used widely in clinical therapy for long-term treatment. It is also well known to be a promoter of rat hepatocarcinogenesis and is an example of a non-genotoxic hepatocarcinogen (5, 6) .
Thus PB does not demonstrate mutagenicity in short-term studies, but long-term feeding results in hepatocarcinogenicity (7, 8) . This may be due to promoting effects on spontaneously initiated hepatocytes (9, 10) . In considering the human risk of PB hepatocarcinogenicity, it is of great interest whether a practical threshold for the promoting effect exists. In the past, dose-response studies for promoting activity of PB have been performed, but this question remains unanswered (11) (12) (13) .
It is generally accepted that thresholds do not exist for genotoxic carcinogens from the point of view that the initiation of cells is an irreversible genetic change (14, 15) . However, non-genotoxic carcinogens and promoters might be expected to demonstrate a threshold level because they act in an epigenetic fashion. Previous studies suggested the existence of a threshold for the promoting activity of PB. Kitagawa et al. reported anticarcinogenic effects of PB when given simultaneously with a hepatocarcinogen, 3Ј-methyl-4-(dimethylamino)-azobenzene, suggesting that its influence is complex (16) . In fact, Pitot et al. and Maekawa et al. reported that administration of low dose PB after diethylnitrosamine (DEN) initiation slightly decreased the number and areas of enzyme-altered foci in rat two-stage hepatocarcinogenesis models (17, 18) .
For the present investigation of dose-related promoting effects of PB, an established in vivo medium-term bioassay system (Ito test) was applied (19) . It is useful for accurate prediction of hepatocarcinogenicity and promoting or inhibitory activity of chemicals and is supported by background data for over 200 chemicals (20) . Furthermore, good agreement between this medium-term bioassay and long-term experimental results for hepatocarcinogenicity has been shown (21) . It is appropriate for assessment of low dose effects of chemicals because of its high sensitivity (19, 20, 22) . Hagiwara et al. examined the dose dependence of PB promoting activity (8-500 p.p.m.) using the Ito test and found that the lower doses (Ͻ15 p.p.m.) caused inhibition (23) .
In this study, we investigated the dose dependence of PB promoting activity in more detail (0.01-500 p.p.m.) using the Ito test to help elucidate a practical threshold level. An assessment of P-450 and growth factor induction was included to cast light on mechanisms.
Materials and methods

Animals
A total of 292 male 5-week-old F344 rats were purchased from Charles River Japan (Hino, Shiga, Japan). They were housed in an animal room maintained on a 12 h (7:00-19:00) light/dark cycle, at a constant temperature of 25 Ϯ 1°C and a relative humidity of 55 Ϯ 5%. The animals were observed daily and were used after a 1 week acclimation period for the experiments detailed below.
Chemicals
Phenobarbital sodium salt (CAS no. 57-30-7) (purity ജ98%) was purchased from Wako Pure Chemical Industries (Osaka, Japan). DEN was from Tokyo Kasei Kogyo (Tokyo, Japan).
Treatment
In experiment 1, 100 male 6-week-old F344 rats were allocated to seven groups (groups 1-6, 15 rats/group; group 7, 10 rats/group). All rats were given a single i.p. injection of DEN (200 mg/kg body wt) dissolved in saline to initiate hepatocarcinogenesis. After 2 weeks on basal diet, they were administered diets containing PB at doses of 0 (control), 1, 2, 4, 7.5, 15 or 500 p.p.m. for 6 weeks from weeks 3 to 8. Animals were subjected to twothirds partial hepatectomy at week 3 to maximize any interaction between proliferation and the effects of the test chemicals. All survivors were killed under ether anesthesia for examination at week 8. The livers were examined for immunohistochemical staining and western blotting analysis of P-450 proteins.
Experiments 2 and 3 featured the same medium-term bioassay system as experiment 1. In experiment 2 a total 60 male 6-week-old F344 rats were divided into four groups (15 rats/group). They received diet containing PB at doses of 0 (control), 0.01, 0.1 or 0.5 p.p.m. for 6 weeks. Experiment 3 was conducted to confirm previous data. One hundred and thirty two male 6-weekold F344 rats were divided into 11 groups (12 rats/group) and administered diet containing PB at doses of 0 (control), 1, 2, 4, 7.5, 15, 30, 60, 125, 250 or 500 p.p.m. for 6 weeks. All rats were killed at week 8 and livers were examined immunohistochemically for glutathione S-transferase placental form (GST-P) expression.
Tissue processing
At autopsy livers were quickly dissected out, weighted and 2-3 mm thick sections from three lobes were fixed in 10% buffered formalin and embedded in paraffin wax. Sections cut at 4 µm were used for immunohistochemistry. The remaining liver tissue was preserved in liquid nitrogen and subjected to the western blotting analysis.
Immunohistochemistry for GST-P, TGF-α and TGF-β
The avidin-biotin complex method was used to demonstrate GST-P-positive liver foci in experiments 1-3 (24). After deparaffinization, liver sections were treated sequentially with 3% H 2 O 2 , normal goat serum, rabbit anti rat GST-P (1:2000, 37°C, 2 h) (provided by Prof. Tsuchida, Hirosaki University), biotinlabeled goat anti-rabbit IgG and avidin-biotin-peroxidase complex (ABC kit; Vector Laboratories, Burlingame, CA). The sites of peroxidase binding were demonstrated by the diaminobenzidine method. The tissue sections were lightly counterstained with hematoxylin to facilitate orientation.
Immunohistochemical staining for transforming growth factor (TGF)-α or TGF-β was also performed using the ABC method in experiment 1. A standard protocol was followed for demonstration of antibody binding with the addition of a trypsin pre-treatment step (0.1% in phosphate-buffered saline, 37°C, 15 min) before incubation with antibody against TGF-α (1:100, 4°C, overnight) (mouse monoclonal IgG 2 ; Oncogene Science, Uniondate, NY) and microwave processing in 10 mM citrate buffer (10 min) before incubation with anti-TGF-β1, β2, β3 antibody (1:100, room temperature, overnight) (mouse monoclonal IgG 1 ; Genzyme, Cambridge, MA). As a negative control, normal rabbit or mouse serum was used instead of the first antibody.
For the staining of serial sections to allow comparisons, GST-P staining was performed with alkaline phosphatase-labeled avidin-biotin complex and the new fuchsin substrate system (Dako Japan, Kyoto, Japan).
Quantitative assessment of GST-P-and TGF-α-positive foci
In this study the measurements of foci were assessed using two-dimensional evaluation (25, 26) . The numbers and areas of GST-P-(experiments 1-3) or TGF-α-positive (experiment 1) foci Ͼ0.2 mm in diameter and the total areas of the liver sections were measured using a color image processor (experiment 1, VIP-21 C; Olympus-Ikegami Tsushin, Tokyo, Japan; experiment 2, SPICCA-II; Nippon Avionics, Tokyo, Japan; experiment 3, IPAP; Sumica Technos, Osaka, Japan) (27) and the numbers and areas of foci/cm 2 of liver sections were calculated.
Analysis of hepatic P-450 protein levels
In experiment 1 western blotting analysis of P-450s protein levels was carried out as described previously (28) . Total amounts were estimated by the method of Omura and Sato (29) . Protein concentration was measured after Lowry et al. (30) . SDS-PAGE was conducted following the method of Laemmli (31) .
Statistical evaluation
Statistical analysis of P-450s protein levels was conducted using analysis of variance (ANOVA) and Duncan's method. Other data were evaluated using Student's t-test according to Welch.
Results
Final body and relative liver weights and PB intake data for experiments 1-3 are shown in Table I . Final average body weights and food consumption of rats exposed to PB did not significantly differ from respective control group values. Relative liver weights in the 60, 125, 250 and 500 p.p.m. groups were significantly increased in a dose-related manner as compared with the DEN alone control group values.
The data for GST-P-positive foci (per cm 2 liver tissue) in experiments 1-3 are given in Figures 1 and 2 and Table II . In experiment 1 the numbers and areas of GST-P-positive foci in rats given 500 p.p.m. PB were significantly increased, while those for rats given 15 p.p.m. PB were similar to the control values. In rats given 1, 2, 4 and 7.5 p.p.m. PB a tendency for decrease was noted, significance being reached for numbers with 2 p.p.m. and areas with 1 and 2 p.p.m.. In experiment 2 the numbers and areas of GST-P-positive foci in rats given 0.01, 0.1 or 0.5 p.p.m. PB were comparable with the control values. In experiment 3, conducted to confirm the results of experiment 1 and previous studies (23) , the data for GST-P was essentially the same as found previously. Significant increases were noted with 60, 125, 250 and 500 p.p.m. and decreases with 2 and 4 p.p.m.
Quantitative data for TGF-α-positive foci in the liver in experiment 1 are shown in Figure 3 . The numbers and areas of TGF-α-positive foci in rats given 500 p.p.m. PB were significantly increased and the values for rats given low dose PB (1, 2, 4, 7.5 and 15 p.p.m.) demonstrated a tendency to decrease. In this case the area for 15 p.p.m. was significantly lower than that of the control group.
Results for staining for GST-P and TGF-α using serial liver sections are shown in Figure 4 . Approximately 1/8-1/10th of the GST-P-positive foci in the livers treated with PB were also positive for TGF-α.
Immunohistochemical staining for TGF-β revealed that TGF-α-positive foci were almost always negative for TGF-β ( Figure 5 ). Nuclei of background hepatocytes were, however, stained with antibody to TGF-β.
The results of quantitative analysis of P-450s protein levels in the livers in experiment 1 are shown in Figure 6 . CYP2B1 protein was increased in a nearly dose-dependent manner by PB administration, although the levels of protein were low throughout, and protein 2C6 was also increased in a dosedependent manner. Significant increases in proteins CYP2B1 and 2C6 were noted with 500 p.p.m. PB. On the other hand, protein CYP3A2 was significantly increased at 500 p.p.m. and reversibly decreased at low dose (1-15 p.p.m.), significance being reached at 1 p.p.m. At the low doses a good correlation between changes in GST-P-positive foci and CYP3A2 was observed.
Discussion
PB has been reported to exert weak hepatocarcinogenicity and hepatopromotion potential in rats and mice (5, 6 ). The present study indicated clear dose-dependent increases in numbers and areas of GST-P-positive foci with PB in the range 60-500 p.p.m. In contrast, 15-30 p.p.m. PB did not appear to have any effect and a tendency for inhibition was observed with the low dose groups (1-7.5 p.p.m.). Examination of the influence of PB at 0.01-0.5 p.p.m. again revealed results comparable with the control values. Thus a practical threshold level exists for promoting effects. TGF-α-positive foci also demonstrated similar results to those for GST-P-positive foci, the decrease observed with low dose treatment being very interesting in view of the correlation of TGF-α with tumor growth (32) (33) (34) . Although expression of TGF-α tended to decrease with the middle doses (15 p.p.m.), we think that the results are basically similar to those for GST-P-positive foci. The staining for GST-P and TGF-α using serial sections showed TGF-α-positive foci to also be GST-P positive and much fewer, in accordance with a previous report (35) . Thus expression of TGF-α may play a role in progression of hepatocarcinogenesis.
The mechanism by which PB promotes the formation of hepatocellular carcinomas is still poorly understood. It has been reported that exposure of rats to PB increases the hepatic concentration of the potent mito-inhibitory factor TGF-β, while, in contrast, preneoplastic lesions in the liver induced by DEN do not demonstrate elevated levels (36,37). Braun et al. reported that TGF-β is produced by non-parenchymal cells in liver and functions as a paracrine inhibitory factor (38) . We suspect that we may detect TGF-β bound to receptors and our results may reflect receptor levels in hepatocytes. It is known that PB treatment changes the levels of the receptor for TGF-β in hepatocytes (39) .
We also found that TGF-α-positive foci are almost always negative for TGF-β and suggested a correlation with the promoting effects of PB. However, any relationship of TGF-β with the weak inhibitory effects of PB was not clear in the present study.
The inhibitory effects of PB may be the result of stimulation of hepatic drug-metabolizing enzymes which detoxify carcinogens (2) . In the rat liver CYP2B1, 2C6 and 3A2 are known to be induced by administration of PB (23, 40, 41) . The results on CYP3A2 induction suggested a close correlation with expression of GST-P-positive foci. The correlation in the low dose range was in especially good agreement, in contrast to the results for CYP2B1 and 2C6. However, the relevance of these P-450 proteins for the promoting activity of PB is unclear. The localization of the induced P-450 is important and PB is in fact known to decrease expression of CYP proteins in hyperplastic nodules of the rat liver (23) .
Regarding tumor promotion, cell proliferation and apoptosis are both important factors. Kolaja et al. looked at these in hepatic preneoplastic lesions in rats and mice treated with DEN followed by PB treatment (11) . They demonstrated enhancement of cell proliferation and inhibition of apoptosis by PB treatment (doses of 100 and 500 p.p.m.), but no effect with a dose of 10 p.p.m. PB. It may be that administration of low dose PB enhances the proportion of cells undergoing apoptosis rather than proliferation, but data on very low doses of PB (1-10 p.p.m.) are limited. Furthermore, we should examine these not only in altered foci but also in surrounding hepatocytes. Previously, Goldsworthy et al. (12) reported no promotion by PB below 10 p.p.m. with regard to numbers of enzymealtered foci. The finding of a slight decrease in altered hepatic foci with 10 p.p.m. PB was found by Pitot et al. (17) and Maekawa et al. noted similar results with 1 p.p.m. PB (18) . The dose dependence of tumor promotion has been clearly shown in a multistage carcinogenesis model (42, 43) . In the present study we examined a number of doses of PB and demonstrated a reverse action of low dose PB with statistical significance. The data strongly suggest the presence of a threshold for promoting effects. It is considered that, independent of the underlying mechanisms, a no-effect level is inherent in promotion by non-genotoxic agents, so that a threshold level should be expected. The clinical dose of PB for humans is 30-200 mg/person/ day, which is roughly equivalent to 10-60 p.p.m. in the rat study. Although differences in the susceptibility between man and rat must be taken into account, this range may be critical for the promoting effects of PB. It remains to be confirmed that other promoters show similar threshold effects and that this is also the case with long-term administration of low doses of PB.
